DB:F6T

Stock Analysis Report

Executive Summary

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Fate Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: F6T's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.7%

F6T

11.3%

DE Biotechs

7.1%

DE Market


1 Year Return

35.7%

F6T

-5.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: F6T exceeded the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: F6T exceeded the German Market which returned -17.5% over the past year.


Shareholder returns

F6TIndustryMarket
7 Day-8.7%11.3%7.1%
30 Day-19.8%-8.0%-20.0%
90 Day20.0%-22.7%-26.1%
1 Year35.7%35.7%-4.9%-5.1%-15.0%-17.5%
3 Year404.1%404.1%17.7%16.4%-18.8%-25.8%
5 Year376.3%376.3%-5.1%-7.5%-17.9%-29.2%

Price Volatility Vs. Market

How volatile is Fate Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Fate Therapeutics undervalued compared to its fair value and its price relative to the market?

6.86x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate F6T's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate F6T's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: F6T is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: F6T is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate F6T's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: F6T is overvalued based on its PB Ratio (6.9x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Fate Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?

5.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: F6T is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: F6T is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: F6T is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: F6T's revenue (59.1% per year) is forecast to grow faster than the German market (4.2% per year).

High Growth Revenue: F6T's revenue (59.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if F6T's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Fate Therapeutics performed over the past 5 years?

-27.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: F6T is currently unprofitable.

Growing Profit Margin: F6T is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: F6T is unprofitable, and losses have increased over the past 5 years at a rate of -27.5% per year.

Accelerating Growth: Unable to compare F6T's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: F6T is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: F6T has a negative Return on Equity (-40.1%), as it is currently unprofitable.


Next Steps

Financial Health

How is Fate Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: F6T's short term assets ($227.1M) exceed its short term liabilities ($27.8M).

Long Term Liabilities: F6T's short term assets ($227.1M) exceed its long term liabilities ($29.7M).


Debt to Equity History and Analysis

Debt Level: F6T is debt free.

Reducing Debt: F6T has no debt compared to 5 years ago when its debt to equity ratio was 69.4%.


Balance Sheet

Inventory Level: F6T has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if F6T's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: F6T has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: F6T has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of -25% each year.


Next Steps

Dividend

What is Fate Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate F6T's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate F6T's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if F6T's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if F6T's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of F6T's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

J. Wolchko (49yo)

4.25s

Tenure

US$10,720,955

Compensation

Mr. J. Scott Wolchko is the Founder of Fate Therapeutics, Inc. and has been its Chief Executive Officer and President since December 1, 2015. Mr. Wolchko served as Principal Financial Officer and Principal ...


CEO Compensation Analysis

Compensation vs Market: J.'s total compensation ($USD10.72M) is above average for companies of similar size in the German market ($USD1.86M).

Compensation vs Earnings: J.'s compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
J. Wolchko
Founder4.25yrsUS$10.72m0.14% $2.1m
Daniel Shoemaker
Chief Scientific Officer4.83yrsUS$2.82m0.12% $1.8m
Cindy Tahl
General Counsel & Corporate Secretary4.42yrsUS$2.82m0.059% $890.5k
Bahram Valamehr
Chief Development Officer2.17yrsUS$2.82m0.042% $644.4k
Wen Wang
Senior Vice President of Technical Operations1.42yrsno datano data
Jim Beitel
Senior Vice President of Corporate Development2.5yrsno datano data
Sarah Cooley
Senior Vice President of Clinical Translation1yrno datano data
Yu-Waye Chu
Senior Vice President of Clinical Development0.17yrno datano data

2.3yrs

Average Tenure

47.5yo

Average Age

Experienced Management: F6T's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
J. Wolchko
Founder4.25yrsUS$10.72m0.14% $2.1m
William Rastetter
Chairman8.33yrsUS$277.14k0.76% $11.6m
John Mendlein
Vice Chairman of the Board8.33yrsUS$245.98k0.21% $3.1m
Robert Langer
Member of Scientific Advisory Boardno datano datano data
Amir Nashat
Independent Director12.5yrsUS$234.45kno data
Bennett Shapiro
Member of Scientific Advisory Boardno datano datano data
Stuart Orkin
Member of Scientific Advisory Board9.83yrsno datano data
Timothy Coughlin
Independent Director6.58yrsUS$250.95k0.074% $1.1m
Sean Morrison
Member of Scientific Advisory Board9.83yrsno datano data
Mark Krasnow
Member of Scientific Advisory Board9.83yrsno datano data

9.1yrs

Average Tenure

59yo

Average Age

Experienced Board: F6T's board of directors are considered experienced (9.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: F6T insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.3%.


Top Shareholders

Company Information

Fate Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Fate Therapeutics, Inc.
  • Ticker: F6T
  • Exchange: DB
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.684b
  • Listing Market Cap: US$1.519b
  • Shares outstanding: 75.94m
  • Website: https://www.fatetherapeutics.com

Number of Employees


Location

  • Fate Therapeutics, Inc.
  • 3535 General Atomics Court
  • Suite 200
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FATENasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDOct 2013
F6TDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2013

Biography

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy comprising adaptive memory NK cells; FT500, an induced pluripotent stem cell (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516, an iPSC-derived non-cleavable CD16 engineered NK cell product candidate to treat hematologic malignancies and solid tumors; and FT596, a chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies. The company’s immuno-oncology product candidates also include FT538, an NK cell product candidate for treating multiple myeloma; and FT819, a CAR T-cell product candidate for the treatment of liquid and solid tumors. Its immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and FT301, an immuno-regulatory cell product candidate for various disease indications, including graft-versus-host disease, multiple sclerosis, ulcerative colitis, and others. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 23:20
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.